THE FACT ABOUT AGEN EURO THAT NO ONE IS SUGGESTING

Emily Bodnar’s rating is based within the anticipation of major milestones for Agenus in the approaching calendar year, especially the potential filing of the Biologics License Application (BLA) for his or her direct drug prospect, botensilimab (bot). Agenus has dosed in excess of 900 patients with bot across different good tumors, demonstrating